Search results for "RELATIONSHIP"

showing 10 items of 3616 documents

Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men

2004

The aim of the present study was to evaluate whether olive oils high in phenolic compounds influence the oxidative/antioxidative status in humans. Healthy men (n = 12) participated in a double-blind, randomized, crossover study in which 3 olive oils with low (LPC), moderate (MPC), and high (HPC) phenolic content were given as raw doses (25 mL/d) for 4 consecutive days preceded by 10-d washout periods. Volunteers followed a strict very low-antioxidant diet the 3 d before and during the intervention periods. Short-term consumption of olive oils decreased plasma oxidized LDL (oxLDL), 8-oxo-dG in mitochondrial DNA and urine, malondialdehyde in urine (P < 0.05 for linear trend), and increased HD…

AdultMaleTime FactorsMedicine (miscellaneous)Urinemedicine.disease_causeDNA MitochondrialAntioxidantschemistry.chemical_compoundDouble-Blind MethodPhenolsMalondialdehydemedicineHumansPlant OilsPhenolsFood scienceOlive OilGlutathione PeroxidaseNutrition and DieteticsCross-Over StudiesDose-Response Relationship DrugCholesterolCholesterol HDLDeoxyguanosineMalondialdehydePostprandial PeriodDietLipoproteins LDLDose–response relationshipVegetable oilPostprandialchemistryBiochemistry8-Hydroxy-2'-DeoxyguanosineOxidation-ReductionOxidative stress
researchProduct

Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease

1986

The dose-dependent inhibition of platelet aggregation by the chemically stable, prostacyclin-mimetic, iloprost, was studied in patients suffering from stage II-III peripheral arterial obliterative disease (PAOD). The study was designed as a randomized placebo-controlled cross-over trial. Iloprost was administered i.v. to six patients at doses of 0.5, 1.0, 2.0 or 3.0 ng/kg X min for 4 h, with an interval of 2-3 days between the infusions. During iloprost infusion, systolic and diastolic arterial blood pressure, heart rate and blood flow in the affected limb remained unchanged. In contrast, there was a considerable, dose-dependent inhibition of ADP- and thrombin-induced platelet aggregation a…

AdultMaleTime FactorsPlatelet AggregationDiastoleHemodynamicsArterial Occlusive DiseasesPlaceboRandom AllocationDrug DiscoveryHeart ratemedicineHumansPlateletIloprostGenetics (clinical)AgedDose-Response Relationship Drugbusiness.industryHemodynamicsCardiovascular AgentsGeneral MedicineMiddle AgedEpoprostenolBlood pressureAnesthesiaCardiovascular agentDrug EvaluationMolecular MedicineFemalelipids (amino acids peptides and proteins)businesscirculatory and respiratory physiologyIloprostmedicine.drugKlinische Wochenschrift
researchProduct

Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis

1999

SUMMARYMethotrexate (MTX) is an effective immunosuppressive agent in various chronic inflammatory diseases such as rheumatoid arthritis (RA). However, its mechanisms of action are only partially understood. In this study, we assessed the effects of MTX on the differentiation of peripheral blood (PB) CD4+CD45RA ‘naive’ and CD4+CD45RO ‘memory’ T cells from healthy controls and patients with RA. Accordingly, purified T cells were primed and restimulated in vitro via the T cell receptor (TCR) in the presence of IL-2 to generate effector T cells secreting large amounts of Th1 and Th2 cytokines. We observed that low doses of MTX strongly suppress TNF and to a lesser extent interferon-gamma (IFN-γ…

AdultMaleTime FactorsT-LymphocytesT cellImmunologyReceptors Antigen T-CellPriming (immunology)Enzyme-Linked Immunosorbent AssayMonocytesArthritis RheumatoidInterferon-gammaAntigens CDimmune system diseasesmedicineHumansImmunology and AllergyCytotoxic T cellCells CulturedB-LymphocytesDose-Response Relationship DrugTumor Necrosis Factor-alphabusiness.industryMonocyteSynovial MembraneT-cell receptorCell DifferentiationOriginal ArticlesT lymphocyteMiddle Agedmedicine.diseaseMethotrexatemedicine.anatomical_structureAntirheumatic AgentsRheumatoid arthritisImmunologyCytokinesFemaleTumor necrosis factor alphabusinessClinical and Experimental Immunology
researchProduct

Time course of adverse events most commonly associated with topiramate for migraine prevention

2007

The efficacy, safety and tolerability of topiramate has been demonstrated in three large multicenter, randomized, double-blind, placebo-controlled trials. To characterize the time course of adverse events (AEs) that led to treatment discontinuation in/=2% of patients who received topiramate 100 mg/day during three pivotal, multicenter, randomized, double-blind, placebo-controlled, and 26-week trials. The pooled population comprised all randomized patients who reported safety data during the double-blind phase (topiramate 100 mg/day, n = 386; placebo n = 372), which consisted of a 4-week titration period and a 22-week maintenance period. Incidence, time to onset, and cumulative mean rate of …

AdultMaleTopiramateTime FactorsNauseaMigraine DisordersPopulationFructosePlaceboTimelaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialTopiramatelawmedicineHumansParesthesiaeducationFatigueeducation.field_of_studyDose-Response Relationship Drugbusiness.industryNauseaMiddle Agedmedicine.diseaseAnorexiaDiscontinuationWithholding TreatmentNeurologyTolerabilityMigraineAnesthesiaPatient ComplianceAnticonvulsantsFemaleNeurology (clinical)medicine.symptomCognition Disordersbusinessmedicine.drugEuropean Journal of Neurology
researchProduct

Transcranial Doppler diagnosis of cerebral vasospasm following subarachnoid haemorrhage: correlation and analysis of results in relation to the age o…

1994

A retrospective analysis was undertaken to determine whether cerebral vasospasm following subarachnoid haemorrhage (SAH) correlates with the age of patients. For at least 3 weeks after bleeding 80 subjects underwent very close follow-up with clinical examination and transcranial Doppler records of the blood velocities within the basal cerebral arteries. Firstly a correlation between measured maximal mean blood flow velocities and age was made. Secondly, according to their age and the maximum of recorded mean velocities (v), the patients were divided into groups as follows: age 55 years or less, age more than 55 years; and maximum velocity v190 cm/s, 90 cm/sv2120 cm/s, 120 cm/sv3160 cm/s, v4…

AdultMaleUltrasonography Doppler TranscranialCerebral arteriesAneurysm RupturedDrug Administration ScheduleCerebral vasospasmMedicineHumanscardiovascular diseasesNeuroradiologyAgedRetrospective StudiesDose-Response Relationship Drugbusiness.industryVascular diseaseAge FactorsVasospasmIntracranial AneurysmLaser Doppler velocimetryMiddle AgedSubarachnoid Hemorrhagemedicine.diseasenervous system diseasesTranscranial Dopplermedicine.anatomical_structureIschemic Attack TransientAnesthesiaCerebrovascular CirculationSurgeryFemaleNimodipineNeurology (clinical)businessBlood Flow VelocityArteryFollow-Up StudiesActa neurochirurgica
researchProduct

Continuous therapy with transdermal nitroglycerin does not affect biomarkers of vascular inflammation and injury in healthy volunteers.

2009

Continuous exposure to nitroglycerin (GTN) results in development of tolerance and is associated with increased free radical production and abnormal endothelial function. Elevated plasma biomarkers of inflammation have been shown to be associated with endothelial dysfunction in most cardiovascular conditions. It remains unclear whether exposure to GTN is also associated with increased biomarkers of endothelial and vascular injury or vascular inflammation. In an investigator-blind study, a total of 28 healthy volunteers were randomized to continuous therapy with GTN (0.6 mg/h 24 h/day for 7 days) or no therapy. Venous blood was collected on day 0 and day 7. Plasma levels of markers such as …

AdultMaleVasculitisTime FactorsEndotheliumAdolescentPhysiologyVasodilator AgentsInflammationPharmacologyAdministration CutaneousArginineLesionNitroglycerinYoung AdultPhysiology (medical)MedicineHumansEndothelial dysfunctionTransdermalPharmacologyDose-Response Relationship Drugbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaGeneral MedicineVenous bloodmedicine.diseaseLipoproteins LDLDose–response relationshipP-Selectinmedicine.anatomical_structureAnesthesiacardiovascular systemTumor necrosis factor alphaEndothelium Vascularmedicine.symptombusinessCell Adhesion MoleculesBiomarkerscirculatory and respiratory physiologyCanadian journal of physiology and pharmacology
researchProduct

Contractile responses of human thyroid arteries to vasopressin

2013

Abstract Aims In the present study we investigated the intervention of nitric oxide and prostacyclin in the responses to vasopressin of isolated thyroid arteries obtained from multi-organ donors. Main methods Paired artery rings from glandular branches of the superior thyroid artery, one normal and the other deendothelised, were mounted in organ baths for isometric recording of tension. Concentration–response curves to vasopressin were determined in the absence and in the presence of either the vasopressin V 1 receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 − 8  M), the nitric oxide synthase inhibitor N G -monomethyl- l -arginine ( L -NMMA, 10 − 4  M), or the inhibitor of prostaglandins indom…

AdultMaleVasopressinmedicine.medical_specialtyEndotheliumVasopressinsIndomethacinThyroid GlandProstacyclinIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyNitric oxideSuperior thyroid arterychemistry.chemical_compoundmedicine.arteryInternal medicinemedicineHumansDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsAgedVasopressin receptoromega-N-MethylarginineDose-Response Relationship DrugbiologyChemistryThyroidArteriesGeneral MedicineMiddle AgedArginine VasopressinNitric oxide synthaseEndocrinologymedicine.anatomical_structureVasoconstrictionbiology.proteinFemalehormones hormone substitutes and hormone antagonistsmedicine.drugLife Sciences
researchProduct

Endothelium-independent contractions of human cerebral arteries in response to vasopressin.

1990

We studied the effects of vasopressin in isolated segments from branches (500-700 micrograms in external diameter) of human middle cerebral arteries obtained during autopsy of 15 patients who had died 3-8 hours before. Paired segments, one normal and the other de-endothelized by gentle rubbing, were mounted for isometric recording of tension in organ baths. In 11 normal segments, vasopressin produced concentration-dependent contractions with an EC50 of 7.0 X 10(-10) M. Removal of the endothelium from 12 segments did not significantly affect vasopressin-induced contractions. Vasopressin produced further contractions in arterial segments with (n = 4) or without (n = 5) endothelium precontract…

AdultMaleVasopressinmedicine.medical_specialtyEndotheliummedicine.drug_classVasopressinsCerebral arteriesNeuropeptideIn Vitro TechniquesPotassium Chloridemedicine.arteryInternal medicinemedicineHumansAgedAdvanced and Specialized NursingDose-Response Relationship Drugbusiness.industryOsmolar ConcentrationCerebral ArteriesMiddle AgedReceptor antagonistAcetylcholineArginine Vasopressinmedicine.anatomical_structureEndocrinologyVasoconstrictionMiddle cerebral arteryFemaleNeurology (clinical)Endothelium Vascularmedicine.symptomCardiology and Cardiovascular MedicinebusinessAcetylcholineVasoconstrictionmedicine.drugStroke
researchProduct

Effects of vasopressin on human renal arteries

1996

The effects of vasopressin were studied in isolated rings from branches (2-3 mm in external diameter) of human renal arteries obtained from 18 patients undergoing nephrectomy for non-obstructive neoplasia. In arterial rings under resting tension, vasopressin produced concentration-dependent and endothelium-independent contractions with an EC 50 of 9.1 x 10 -10 mol L -1 . The vasopressin V 1 receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 -6 mol L -1 ) displaced the control curve to vasopressin 564-fold to the right in a parallel manner. In precontracted arterial rings and previously treated with the V 1 antagonist (10 -6 mol L -1 ) vasopressin caused endothelium-independent relaxation. The re…

AdultMaleVasopressinmedicine.medical_specialtyVasopressinsmedicine.drug_classMuscle RelaxationIndomethacinClinical BiochemistryNeuropeptideBiologyBiochemistryNorepinephrineRenal ArteryInternal medicinemedicineHumansVasoconstrictor AgentsAgedVasopressin receptorKidneyDose-Response Relationship DrugAnti-Inflammatory Agents Non-SteroidalAntagonistGeneral MedicineMiddle AgedReceptor antagonistmedicine.anatomical_structureEndocrinologyCirculatory systemFemaleEndothelium Vascularmedicine.symptomhormones hormone substitutes and hormone antagonistsVasoconstrictionMuscle ContractionEuropean Journal of Clinical Investigation
researchProduct

Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain

2007

What is already known about this subject • Despite encouraging effects of N-methyl-D-aspartate (NMDA) receptor antagonists in reducing neuropathic pain of different aetiologies, the clinical use of these agents has been limited by their mainly psychotropic side-effects. • In a recent study in healthy volunteers, CNS 5161, a novel noncompetetive NMDA receptor antagonist, was well tolerated up to a dosage of 2000 µg without psychotropic side-effects. • This is the first study to evaluate the maximal tolerated dosage of CNS 5161 and to gain experience about the analgesic effect of CNS 5161 in patients with different pain syndromes. What this study adds • In patients with neuropathic pain CNS 5…

AdultMaleVisual analogue scaleAnalgesicPlaceboGuanidinesReceptors N-Methyl-D-Aspartatechemistry.chemical_compoundDrug SafetyDouble-Blind MethodMedicineHumansPharmacology (medical)Glutamate receptor antagonistSulfhydryl CompoundsAdverse effectAgedPain MeasurementPharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryTherapeutic effectMiddle AgedBlood pressurechemistryAnesthesiaNeuropathic painNeuralgiaFemalebusiness
researchProduct